Genetic Signatures Ltd has released a press release.
CE-IVD Mark for Respiratory Pathogen Detection Kit
Filed with ASX ·
Watch Genetic Signatures' latest callGenetic Signatures (ASX:GSS) Q4 2026 Earnings Call · Replay · Aug 25Read the transcript of Genetic Signatures (ASX:GSS) Q4 2026 Earnings Call6ix hasn’t read this filing yet.
Genetic Signatures Ltd. on 6ix
Earlier from Genetic Signatures
- $2.6m R&D refund received
- Chairmans Address to Shareholders
- Investor presentation
- Appendix 4E and 2018 Financial Report
- Additional Tax Incentive from understatement FY17 R&D Claim
Later from Genetic Signatures
- Appendix 4C - quarterly
- TGA registration for Respiratory Pathogen Detection Kit
- Appendix 4C and quarterly update
- Appendix 4E & Full Year Statutory Accounts
- Genetic Signatures completes $35m placement
Follow Genetic Signatures into a list and get an email when it puts out news.
Follow Genetic Signatures